 |
TransPharma Announces
Successful Completion of Phase 2 Trial of ViaDerm-hPTH (1-34) in
Postmenopausal Women with Osteoporosis
Lod, Israel, September 1, 2009 – TransPharma Medical Ltd., a specialty
pharmaceutical company focused on the development and commercialization of
drug products utilizing a proprietary active transdermal drug delivery
technology, announced today the successful completion of the Phase 2A trial of
ViaDerm.
September 1, 2009
Read More |
| |
|
|
TransPharma Receives
European CE Mark Approval for its Transdermal Drug Delivery Device
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the
development and commercialization of drug products utilizing a proprietary
active transdermal drug delivery technology, announced today that it received
European CE Mark approval for its ViaDerm, a transdermal drug delivery device.
December 15, 2008
Read More |
| |
|
|
Frost & Sullivan Honours
TransPharma Medical for its Innovative ViaDerm Drug Delivery System
The 2008 Frost & Sullivan European Transdermal Drug Delivery Product
Innovation Award is conferred on Israel-based TransPharma Medical Ltd. in
recognition of its innovative ViaDerm drug delivery system. The company’s two
flagship drug product development programs - ViaDerm hPTH (1-34) for the
treatment of osteoporosis and ViaDerm-hGH for the treatment of human growth
hormone deficiency –both in phase 2 of clinical development.
August 2, 2008
Read More |
| |
|
|
Lilly and TransPharma
Medical Announce Licensing and Development Agreement
Eli Lilly and Company (NYSE:LLY) and TransPharma Medical Ltd. today announced
that the two companies have entered into a licensing and development agreement
related to TransPharma's ViaDerm-hPTH (1-34) product for the treatment of
osteoporosis.
June 12, 2008
Read More |
| |
|
| |
|
|
TransPharma Medical
Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery
of hPTH (1-34) for Osteoporosis Treatment |
| |
TransPharma Medical Ltd., a specialty pharmaceutical
company focused on the development and commercialization of drug products
utilizing a proprietary active transdermal drug delivery technology, announced
today promising results of its phase I clinical trials demonstrating the
safety and pharmacokinetic profile of its ViaDerm-hPTH (1-34) product for the
treatment of osteoporosis.
July 9, 2007
Read More |
| |
|
|
TransPharma Medical Receives Second Milestone Payment from Teva Pharmaceutical Industries
|
| |
TransPharma Medical Ltd., a specialty pharmaceutical
company focused on the development and commercialization of drug products
utilizing a proprietary active transdermal drug delivery technology, announced
today it has received its second milestone payment from Teva Pharmaceutical
Industries
June 11, 2007
Read More |
| |
|
|
TransPharma Medical Named
Winner of 2007 Red Herring 100 Europe Award |
 |
| |
TransPharma Medical Ltd., a specialty pharmaceutical
company focused on the development and commercialization of drug products
utilizing a proprietary active transdermal drug delivery technology,
announced today that it has been selected as a recipient of Red Herring 100
Europe.
March 21, 2007
Read more |
|
TransPharma Medical Expands
Board of Directors with Appointment of Industry Veteran Larry Ellberger
|
|
| |
TransPharma Medical Ltd., a specialty pharmaceutical
company focused on the development and commercialization of drug products
utilizing a proprietary active transdermal drug delivery technology,
announced today the appointment of Larry Ellberger to the Company’s Board of
Directors.
March 12, 2007
Read more
|
| |
For Earlier News
|
